Q-omics provides the consensus-scored TGFBR2 profile across patient tissues and cancer cell-line models. TGFBR2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TGFBR2 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, TGFBR2 RNA expression shows 27,771 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BLCA, and LSCC as cancer lineages where TGFBR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TGFBR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TGFBR2 survival associations across molecular data types. TGFBR2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TGFBR2 RNA expression–survival associations across cancer types. High TGFBR2 expression shows unfavorable associations in CESC and LGG, but favorable associations in KIRC, UCS, ESCA and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TGFBR2 RNA expression.
This table summarizes TGFBR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TGFBR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TGFBR2 shows lower tumor expression in BLCA, LUSC, LUAD, KIRP, THCA and KICH. The BLCA box plot shows higher TGFBR2 RNA expression in normal versus tumor tissue (log2 FC = −1.586, t-test p < 0.001).
This table shows molecular features associated with TGFBR2 in patient tissues and cancer cell lines. In patient samples, TGFBR2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TGFBR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
